"Complejo Hospitalario Universitario A Coruna (CHUAC)"
Welcome,         Profile    Billing    Logout  
 2 Trials 
12 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Campelo, Rosario García
ZEAL-1L, NCT04475939 / 2020-002202-20: Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

Calendar Jan 2024 - Jun 2024: From ZEAL-1L trial in combination with Keytruda for stage 3 or 4 NSCLC
Checkmark JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Checkmark [VIRTUAL] First-line (1L Maintenance Therapy with Niraparib (nira + Pembrolizumab (pembro vs Placebo + Pembro in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC: Phase 3 ZEAL-1L Study
Checkmark [VIRTUAL] First-line (1L) maintenance therapy with niraparib (nira) + pembrolizumab (pembro) vs placebo + pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
Checkmark Niraparib (Nira) + pembrolizumab (Pembro) versus placebo (PBO) + Pembro 1L maintenance therapy in advanced non-small cell lung cancer (NSCLC): ZEAL-1L phase 3 study
Recruiting
3
650
Europe, US, RoW
Niraparib, Pembrolizumab, Placebo
GlaxoSmithKline
Lung Cancer, Non-Small Cell
08/24
10/24
NADIM-ADJUVANT, NCT04564157: New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

Checkmark [VIRTUAL] A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.
Recruiting
3
210
Europe
Carboplatin, Paraplatin, Paclitaxel, Taxol, Nivolumab, Opdivo
Fundación GECP
Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
04/27
04/28
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy

Checkmark Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
Recruiting
2/3
250
Europe, Canada, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline, GlaxoSmithKline Research and Devlopment Limited, GlaxoSmithKline Research and Development Limited
Lung Cancer, Non-Small Cell
09/24
01/26
Replay, NCT03526887: Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

Checkmark Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): a preliminary report of the REPLAY phase II trial - cohort I
Recruiting
2
110
Europe
Pembrolizumab
Spanish Lung Cancer Group
Lung Cancer
12/22
12/23
ABC-lung, NCT04245085 / 2019-001687-30: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Recruiting
2
95
Europe, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Carboplatin, Paclitaxel, Pemetrexed, Alimta
European Thoracic Oncology Platform, Roche Pharma AG
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
12/22
03/23
GECP 20/01_Neo-DIANA, NCT04512430: Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Recruiting
2
26
Europe
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Carboplatin, Paraplatin, Pemetrexed, Alimta
Fundación GECP
Non Small Cell Lung Cancer, EGFR Gene Mutation
12/23
12/26
BIMES, NCT05005429 / 2020-004902-67: Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma

Recruiting
2
47
Europe
Bintrafusp alfa, M7824
Fundación GECP
Mesothelioma; Lung
03/25
04/25
NIVIPI-Brain, NCT05012254: Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

Recruiting
2
71
Europe
Ipilimumab, Yervoy, Nivolumab, Opdivo, Carboplatin, Paraplatin, Cisplatin, Cis-diamminedichloroplatinum, Platinol, Paclitaxel, Taxol, Pemetrexed, Pemetrexed disodium; ALIMTA
Fundación GECP
Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer
03/26
12/26
PEERS, NCT05384015: Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

Not yet recruiting
2
85
Europe
Lenvatinib, LENVIMA, KISPLYX, Pembrolizumab, KEYTRUDA, Etoposide, Etoposide Tevagen, Carboplatin, Carboplatin Accord
Fundación GECP
Small Cell Lung Cancer Extensive Stage
07/26
07/27
APOLO, NCT04776447 / 2020-004459-33: Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy.

Recruiting
2
51
Europe
Carboplatin, Carboplatinum, Placlitaxel, Taxol, Atezolizumab, Tecentriq
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Carcinoma Bronchiogenic Stage III, Thoracic Neoplasms
11/26
11/27
MERIT-lung, NCT05398094: Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Recruiting
2
43
Europe
Sotorasib, AMG510
Fundación GECP
Non-small Cell Lung Cancer Stage III, KRAS P.G12C
12/27
12/28
NCT02941458: Thoracic Tumours Register

Checkmark Determination of essential biomarkers in lung cancer: A real-world data study in Spain
Checkmark Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)
Checkmark Tobacco use in lung cancer (LC) patients (p) in Spain
Checkmark Biomarker testing of lung cancer in Spain
Checkmark Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
More
Recruiting
N/A
10000
Europe
Spanish Lung Cancer Group
Thoracic Tumors
12/25
12/30

Download Options